Journals / Tüberküloz ve Toraks / 2015 / Cilt: 63 - Sayı: 3

YKL-40: Obstrüktif uyku apne sendromunda yeni bir inflamatuvar biyobelirteç olarak kullanılabilir mi?

YKL-40: may be use as a new inflammatory biomarker in obstructive sleep apnea syndrome?

Pages
158–164
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The findings suggest that YKL- 40 may be a useful biomarker for inflammation in patients with OSAS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: YKL-40 [chitinase-3 like-1 (CHI3L1)] is a glycoprotein, has been implicated in inflammation, endothelial dysfunction, tissue remodelling and it is accepted as a noninvasive prognostic biomarker for inflammation.
📊
Key Findings & Data:In this study, we aimed to underline usability of serum YKL-40 as an inflammatory biomarker in patients with obstructive sleep apnea syndrome (OSAS).
💡
Conclusion & Impact:The findings suggest that YKL- 40 may be a useful biomarker for inflammation in patients with OSAS.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: YKL-40 [chitinase-3 like-1 (CHI3L1)] is a glycoprotein, has been implicated in inflammation, endothelial dysfunction, tissue remodelling and it is accepted as a noninvasive prognostic biomarker for inflammation. In this study, we aimed to underline usability of serum YKL-40 as an inflammatory biomarker in patients with obstructive sleep apnea syndrome (OSAS). Patients and Methods: Two groups OSAS patients [Group I: Mild-moderate OSAS, n:43; median apnea-hypopnea index: AHI, /hour:18], Group II: Severe OSAS, n: 25; AHI:41.6] and healthy control group [n:25, AHI: 3.6] were included in the study. Serum YKL-40 level was tested in serum samples taken after polysomnography in OSAS patients and control group. In addition, the association of serum YKL-40 level with age, body mass index and polysomnografic parameters were analyzed in the OSAS patient groups. Results: Median serum YKL-40 level was 20.30 ng/mL (range 8.01-73 ng/mL) in mild-moderate OSAS patients, and 22.58 ng/mL (9.17-99 ng/mL in severe OSAS patients, 18 ng/mL (range 7.36-88 ng/mL) in control group (p 0.05). Conclusion: At the end of this study, we found that serum YKL-40 level increase with severity of OSAS. The findings suggest that YKL- 40 may be a useful biomarker for inflammation in patients with OSAS.

Özet

Giriş: YKL-40 [chitinase-3 like-1 (CHI3L1)], inflamasyon, endotel disfonksiyonu, remodellingde rol oynayan ve inflamasyon için noninvaziv prognostik biyobelirteç olarak kabul edilen bir glikoproteindir. Bu çalışmada, obstrüktif uyku apne sendromlu (OSAS) hastalarda YKL-40ın bir inflammatory biyobelirteç olarak kullanılabilirliğini göstermeyi amaçladık. Hastalar ve Metod: Çalışmaya iki grup OSASlı hasta [Grup I: Hafif-Orta OSAS; n: 43, apnea-hypopnea indeksi; AHI, /saat: 18 (7.1- 28.2), Grup II: Ağır OSAS; n: 25, AHI: 41.6 (33.9-86.9)] ve sağlıklı kontrol grubu [n: 25, AHI: 3.6 (0.4-5) ] alındı. Polisomnografi sonrası OSAS'lı hastalar ve kontrol grubunun serum YKL-40 düzeyleri incelendi. Ayrıca OSASlı hasta gruplarında serum YKL-40 düzeyinin yaş, vücut kitle indeksi ve polisomnografik parametreler ile olan ilişkisi araştırıldı. Bulgular: Ortalama serum YKL-40 düzeyi hafif-orta OSASlı hastalarda 20.30 ng/mL (8.01-73 ng/mL), ağır OSASlı hastalarda 22.58 ng/mL (9.17-99 ng/mL) ve kontrol grubunda 18 ng/mL (7.36-88 ng/mL) olarak bulundu (p= 0.01). Hafif-orta OSASda AHI ile (p 0.05). Sonuç: Bu çalışma sonucunda OSASın ağırlığı ile serum YKL-40 düzeyinin birlikte arttığını saptadık. Bu bulgular YKL-40ın OSASlı hastalarda inflamasyon için kullanılabilir bir biyobelirteç olabileceğini düşündürmektedir.

🔖

Cite This Article

KURT, E. B., ARDIÇ, S., UÇAR, F., DURU, S., ŞİMŞEK, B., YÜCE, G., FIRAT, H. (2022). YKL-40: Obstrüktif uyku apne sendromunda yeni bir inflamatuvar biyobelirteç olarak kullanılabilir mi?. Tüberküloz ve Toraks, Cilt: 63 - Sayı: 3, 158–164. https://ajindex.com/articles/618541

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstruktive sleep apnea syndrome patients: mortality. Chest 1988;94:1200-4
  2. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89
  3. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5
  4. Demir A, Ursavaş A, Tana Aslan A, Gülbay B, Çiftçi B, Çuhadaroğlu Ç, et al. Obstrüktif uyku apne sendromu tanı ve tedavi uzlaşı raporu. Türk Toraks Derneği 2012;1-73
  5. Thropy MJ, Broughton RJ, Cohn MA, et al. American Academy of Sleep Medicine. International classification of sleep disorders. Diagnostic and coding manual (ICSD-2). 2nd ed. American Academy of Sleep Medicine: Westchester, IL, 2005
  6. Iber C, Ancoli-Israel S, Chesson A, Quan SF, American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. American Academy of Sleep Medicine: Westchester, IL, 2007
  7. Meoli AL, Casey KR, Clark RW, Coleman JA Jr, Fayle RW, Troell RJ, et al. Hypopnea in sleep-disordered breathing in adults. Sleep 2001;24:469-70
  8. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89
  9. Imeri L, Opp MR. How (and why) the immune system makes us sleep. Nat Rev Neurosci 2009;10:199-210
  10. Mehra R, Storfer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, et al. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med 2006;166:1725-31
  11. Arter JL, Chi DS, Girish M, Fitzgerald SM, Guha B, Krishnaswamy G, et al. Obstructive sleep apnea, inflammation and cardiopulmonary disease. Front Biosci 2004;1:2892- 900
  12. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12
  13. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10
  14. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like